Clinical Trial Update: Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating the combination of cadonilimab and regorafenib as third-line therapy for microsatellite-stable colorectal cancer with liver metast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cadonilimab
• Stivarga (regorafenib)

Snippet

Sponsor: Jin-hong Chen | Conditions: CRC | Phase 2 | Status: RECRUITING